Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms (GM-WGTT)

This study has been completed.
Sponsor:
Collaborator:
General Mills Inc.
Information provided by:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01004484
First received: October 29, 2009
Last updated: December 17, 2010
Last verified: December 2010
  Purpose

Hypothesis:

  • Daily consumption of yogurt containing probiotic bacteria (Bb12) and inulin will significantly decrease whole gut and intestinal segmental transit time
  • The effect of accelerating intestinal transit will be associated with other GI physiology parameters including stool frequency and stool consistency.

Condition Intervention
Non-diarrhea Functional Bowel Symptoms
Other: A probiotic yogurt with inulin
Other: Acidified dairy snack

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Physiological Effects of Yogurt Containing Bifidobacterium Lactis (Bb12) in Subjects With Non-Diarrhea Functional Gastrointestinal Symptoms

Resource links provided by NLM:


Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • The primary outcome measures will be the whole gut (WGTT) and colonic transit time (CTT) as assessed by SmartPill™ [ Time Frame: 10-28 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary outcome measures (a) Stool frequency (b) Stool consistency (c) Gastric emptying and small bowel transit time [ Time Frame: 10-28 days ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: June 2009
Study Completion Date: April 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Yogurt with probiotics and inulin
A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
Other: A probiotic yogurt with inulin
A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
Placebo Comparator: Placebo
Acidified dairy snack without yogurt cultures, probiotic or inulin.
Other: Acidified dairy snack
A 4 oz. cup of acidified dairy snack, once daily.

Detailed Description:

In previous preliminary study we have shown that daily consumption of a probiotic yogurt drink containing probiotic bacteria (Bifidobacterium lactis Bb12) and inulin significantly accelerate colonic transit time in non-patients population with functional bowel symptoms. In this study we investigate the physiologic effect(s) of yogurt with the same bacteria and inulin on gastrointestinal function by assessing its effect on the whole gut and segmental transit time using SmartPill™ - a recently introduced device of measuring intestinal transit time. The proposed study will provide additional information on the effect on the whole gut transit as well as on other segments of the GI tract (stomach and small bowel). Assessment of transit time in the proposed study will be done following 10 to 14 days of the probiotic yogurt consumption.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent.
  2. 18 - 70 y/o.
  3. Existing functional GI symptoms for at least two weeks.
  4. No current prescription treatment of functional GI Symptoms. Over the counter (OTC) medications allowed if still symptomatic despite current OTC therapy.
  5. Normal colonoscopy within the last 3 years if age >50.
  6. Normal initial screening evaluation including medical history, physical examination, and laboratory tests (CBC, ESR, blood chemistry including BUN, electrolytes, serum creatinine, bilirubin, ALT, AST, ALP, amylase, lipase, TSH, and routine stool microbiology).

Exclusion Criteria:

  1. Physician treatment of functional bowel symptoms in the last 10 months.
  2. Current use of prescription medications for functional bowel symptoms.
  3. 1 or more bowel movements per day.
  4. Contraindication to use of Fleets Enema or the balloon expulsion test.
  5. Severe difficulty with defecation and/or recurrent events of unsuccessful defecation with straining.
  6. Severe FBD symptoms at baseline.
  7. Medical diagnosis of FBD
  8. Daily use of OTC anti-pain, anti-diarrheal or laxative medications.
  9. Presence of pre-existing serious, unstable medical condition.
  10. Insulin-dependent Diabetes Mellitus.
  11. Current diagnosis of major psychiatric disorder or suicide attempt within the last two years.
  12. History of alcohol or substance abuse within two years.
  13. Treatment for malignancy other than BCC or SCC within the last 5 years.
  14. Self-diagnosis of lactase deficiency that explains symptoms (i.e., symptoms resolved or reduced significantly with lactose-free diet.)
  15. Participation in a drug study within the last 21 days.
  16. Antibiotic treatment or probiotic products consumption during the last 4 weeks.
  17. Predisposition to infection (i.e. immune system compromised, rheumatic heart disease, artificial valve, history of bacterial endocarditis, active bacterial disease, etc).
  18. History of gastric bezoar (masses trapped in the gastrointestinal tract).
  19. Disorders of swallowing and/or severe difficulty swallowing (dysphagia) food or pills.
  20. Suspected strictures, fistulas, colon cancer or other physiological GI obstruction.
  21. Allergies to components of the Smart Bar: Granola (Rolled Oats, Evaporated Cane Juice, Expeller Pressed Canola Oil, Defatted Wheat Germ, Oat Flour, Brown Rice Syrup, Molasses, Salt, Natural Flavor, Soy Lecithin), Whey Crisp, Rice Syrup, Corn Syrup, Whey Protein Isolate, Invert Sugar, Puffed Wheat, Apples, Maltodextrin, Sorbitol, Apple Juice Concentrate, Partially Hydrogenated Vegetable Oil (Cottonseed, Soybean), Honey, Natural and Artificial Flavor, Salt, Vanilla.
  22. Prior GI surgery except for removal of gall bladder or appendix; prior stomach surgery for acid reflux disease (Nissen fundoplication).
  23. Abdominal surgery within the past 3 months.
  24. History of inflammatory bowel disease.
  25. History of inflammation of the lining of the gastrointestinal tract (diverticulitis or diverticulosis), tightening of bowels (diverticular stricture), and other intestinal strictures (per self report).
  26. Body Mass Index (BMI) > 40
  27. Female of childbearing age not practicing birth control and/or pregnant or lactating.
  28. Cardiovascular, endocrine, renal, or other chronic disease likely to affect GI motility.
  29. Use of medical device such as a pacemaker, infusion pump, or insulin pump.
  30. Use of following prohibited medications for 1 day prior to the SmartPill ingestion and the day of SmartPill ingestion: (a) Medication to alter gastric pH (Proton Pump Inhibitors); (b) antacids;
  31. Use of following prohibited medications for 3 days prior to the SmartPill ingestion and the day of SmartPill ingestion (a) Medication to lower stomach; (b) Medication that affect GI motility
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01004484

Locations
United States, North Carolina
UNC-CH Program of Digestive Health
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
General Mills Inc.
Investigators
Principal Investigator: Tamar Ringel-Kulka, MD, MPH University of North Carolina, Chapel Hill
  More Information

No publications provided

Responsible Party: Tamar Ringel-Kulka, MD, MPH, The University of North Carolina at Chapel Hill
ClinicalTrials.gov Identifier: NCT01004484     History of Changes
Other Study ID Numbers: 09-0480
Study First Received: October 29, 2009
Last Updated: December 17, 2010
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of North Carolina, Chapel Hill:
non-patients
non-diarrhea functional bowel symptoms

ClinicalTrials.gov processed this record on August 01, 2014